^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cobomarsen (MRG-106)

    i
    Other names: MRG-106, MRG 106, LNA antimiR-155 MRG-106, anti-miR-155 oligonucleotide MRG-106
    Company:
    Viridian Therap
    Drug class:
    miR-155 inhibitor
    over3years
    Targeted eicosanoids profiling reveals a prostaglandin reprogramming in breast Cancer by microRNA-155. (PubMed, J Exp Clin Cancer Res)
    Considering clinical trials targeting PGE2 production largely have focused on the inhibition of Cox1 or Cox2 that showed cardiac toxicity, our data suggest an alternative way for suppressing PGE2 production via the inhibition of miR-155. As the antagomiR of miR-155 (MRG-106) underwent a phase-1 clinical trial, its effect should be considered and analyzed in prostaglandin metabolism in tumor.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MIR155 (MicroRNA 155) • KLF4 (Kruppel-like factor 4)
    |
    miR-155 expression
    |
    cobomarsen (MRG-106)
    over3years
    Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo. (PubMed, Clin Cancer Res)
    Our findings support the potential therapeutic application of cobomarsen in ABC-DLBCL and other types of lymphoma with elevated miR-155 expression.
    Preclinical • Journal
    |
    MIR155 (MicroRNA 155)
    |
    cobomarsen (MRG-106)